Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2.
AuthorSchultz, David C
Johnson, Robert M
Hammond, Holly L
Lee, Jae Seung
Thaiss, Christoph A
Frieman, Matthew B
MetadataShow full item record
AbstractThe SARS-CoV-2 virus has infected more than 261 million people and led to more than 5 million deaths in the last year and a half1 (WHO.org). SARS-CoV-2-infected individuals typically develop mild to severe flu-like symptoms, while infection of a subset of individuals leads to severe to fatal clinical outcomes2. While vaccines have been rapidly developed to combat SARS-CoV-2, there has been a dearth of antiviral therapeutics. There is an urgent need for therapeutics which has been amplified by the emerging threats of variants that may evade vaccines. Large-scale efforts are underway to identify antiviral drugs and we screened ~18,000 drugs for antiviral activity using live virus infection in human respiratory cells and validate 122 drugs with antiviral activity and selectivity against SARS-CoV-2. Amongst these candidates are 16 nucleoside analogues, the largest category of clinically used antivirals. This included the antivirals remdesivir and molnupiravir, which have been approved for use in COVID-19. RNA viruses rely on a high supply of nucleoside triphosphates from the host to efficiently replicate, and we identified a panel of host nucleoside biosynthesis inhibitors as antiviral. Moreover, we found that combining pyrimidine biosynthesis inhibitors with antiviral nucleoside analogues synergistically inhibits SARS-CoV-2 infection in vitro and in vivo against emerging strains of SARS-CoV-2 suggesting a clinical path forward.
Rights/Terms© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/18100
- Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infection.
- Authors: Schultz DC, Johnson RM, Ayyanathan K, Miller J, Whig K, Kamalia B, Dittmar M, Weston S, Hammond HL, Dillen C, Castellana L, Lee JS, Li M, Lee E, Constant S, Ferrer M, Thaiss CA, Frieman MB, Cherry S
- Issue date: 2021 Jun 24
- A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
- Authors: Khan S, Attar F, Bloukh SH, Sharifi M, Nabi F, Bai Q, Khan RH, Falahati M
- Issue date: 2021 Jun 30
- Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
- Authors: Acharya A, Pandey K, Thurman M, Klug E, Trivedi J, Sharma K, Lorson CL, Singh K, Byrareddy SN
- Issue date: 2021 Nov 23
- Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice.
- Authors: Schäfer A, Martinez DR, Won JJ, Meganck RM, Moreira FR, Brown AJ, Gully KL, Zweigart MR, Conrad WS, May SR, Dong S, Kalla R, Chun K, Du Pont V, Babusis D, Tang J, Murakami E, Subramanian R, Barrett KT, Bleier BJ, Bannister R, Feng JY, Bilello JP, Cihlar T, Mackman RL, Montgomery SA, Baric RS, Sheahan TP
- Issue date: 2022 May 4
- Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.
- Authors: Geraghty RJ, Aliota MT, Bonnac LF
- Issue date: 2021 Apr 13